Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial

Publication | Closed Access

DOI

Citations

References

2020

Year

Dirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, Inge De Lepeleire, Martine Robberechts, Evan Friedman, Christian Keicher, Andreas Hüser, Jörg Hofmann, Jay A. Grobler,

The Lancet HIV

Phase 1BPharmacologyAntiviral Drug DevelopmentAntiviral TherapyVirologyConsecutive-panel TrialPharmacotherapyAntiviral DrugHivSingle-dose AdministrationMedicine